25 XP   0   0   10

Cyxone AB
Buy, Hold or Sell?

Let's analyse Cyxone together

PenkeI guess you are interested in Cyxone AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cyxone AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cyxone AB

I send you an email if I find something interesting about Cyxone AB.

Quick analysis of Cyxone (30 sec.)










What can you expect buying and holding a share of Cyxone? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.18
Expected worth in 1 year
kr0.14
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
kr-0.04
Return On Investment
-39.8%

For what price can you sell your share?

Current Price per Share
kr0.09
Expected price per share
kr0.078 - kr0.114
How sure are you?
50%

1. Valuation of Cyxone (5 min.)




Live pricePrice per Share (EOD)

kr0.09

Intrinsic Value Per Share

kr-0.21 - kr-0.18

Total Value Per Share

kr-0.03 - kr0.00

2. Growth of Cyxone (5 min.)




Is Cyxone growing?

Current yearPrevious yearGrowGrow %
How rich?$3.5m$5.2m-$2m-62.7%

How much money is Cyxone making?

Current yearPrevious yearGrowGrow %
Making money-$552.7k-$983.4k$430.6k77.9%
Net Profit Margin-1.4%-8.4%--

How much money comes from the company's main activities?

3. Financial Health of Cyxone (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#780 / 1010

Most Revenue
#1000 / 1010

Most Profit
#214 / 1010

Most Efficient
#446 / 1010

What can you expect buying and holding a share of Cyxone? (5 min.)

Welcome investor! Cyxone's management wants to use your money to grow the business. In return you get a share of Cyxone.

What can you expect buying and holding a share of Cyxone?

First you should know what it really means to hold a share of Cyxone. And how you can make/lose money.

Speculation

The Price per Share of Cyxone is kr0.0928. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cyxone.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cyxone, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.18. Based on the TTM, the Book Value Change Per Share is kr-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cyxone.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.00-3.2%0.00-2.8%0.00-4.9%0.00-4.5%0.00-3.4%
Usd Book Value Change Per Share0.003.4%0.00-0.9%0.000.9%0.00-0.7%0.000.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.003.4%0.00-0.9%0.000.9%0.00-0.7%0.000.6%
Usd Price Per Share0.01-0.03-0.06-0.26-0.38-
Price to Earnings Ratio-0.78--3.40--5.57--17.40--69.56-
Price-to-Total Gains Ratio2.93--3.44--19.78--45.51--81.10-
Price to Book Ratio0.56-2.40-2.67-11.46-23.12-
Price-to-Total Gains Ratio2.93--3.44--19.78--45.51--81.10-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.00852832
Number of shares117256
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (117256 shares)-99.61-78.82
Gains per Year (117256 shares)-398.44-315.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-398-4080-315-325
20-797-8060-631-640
30-1195-12040-946-955
40-1594-16020-1261-1270
50-1992-20000-1576-1585
60-2391-23980-1892-1900
70-2789-27960-2207-2215
80-3188-31940-2522-2530
90-3586-35920-2837-2845
100-3984-39900-3153-3160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.030.00.00.0%0.030.00.00.0%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%12.018.00.040.0%12.018.00.040.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.030.00.0%0.00.030.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%12.018.00.040.0%12.018.00.040.0%

Fundamentals of Cyxone

About Cyxone AB

Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.

Fundamental data was last updated by Penke on 2024-04-21 02:00:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cyxone AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cyxone earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Cyxone to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cyxone AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1.4%+1.4%
TTM-1.4%YOY-8.4%+7.0%
TTM-1.4%5Y-1.9%+0.6%
5Y-1.9%10Y-15,138.0%+15,136.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM-1.4%-216.8%+215.4%
YOY-8.4%-282.3%+273.9%
5Y-1.9%-436.8%+434.9%
10Y-15,138.0%-597.3%-14,540.7%
1.1.2. Return on Assets

Shows how efficient Cyxone is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cyxone to the Biotechnology industry mean.
  • -16.0% Return on Assets means that Cyxone generated kr-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cyxone AB:

  • The MRQ is -16.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.0%TTM-15.0%-1.0%
TTM-15.0%YOY-15.7%+0.7%
TTM-15.0%5Y-16.7%+1.7%
5Y-16.7%10Y-13.4%-3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.0%-13.3%-2.7%
TTM-15.0%-12.8%-2.2%
YOY-15.7%-11.6%-4.1%
5Y-16.7%-13.8%-2.9%
10Y-13.4%-15.6%+2.2%
1.1.3. Return on Equity

Shows how efficient Cyxone is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cyxone to the Biotechnology industry mean.
  • -17.9% Return on Equity means Cyxone generated kr-0.18 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cyxone AB:

  • The MRQ is -17.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.9%TTM-16.4%-1.5%
TTM-16.4%YOY-18.0%+1.5%
TTM-16.4%5Y-18.9%+2.5%
5Y-18.9%10Y-15.1%-3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.9%-16.9%-1.0%
TTM-16.4%-16.1%-0.3%
YOY-18.0%-14.9%-3.1%
5Y-18.9%-19.3%+0.4%
10Y-15.1%-20.1%+5.0%

1.2. Operating Efficiency of Cyxone AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cyxone is operating .

  • Measures how much profit Cyxone makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cyxone to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cyxone AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1.2%+1.2%
TTM-1.2%YOY-8.2%+7.0%
TTM-1.2%5Y-1.9%+0.7%
5Y-1.9%10Y-15,150.3%+15,148.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM-1.2%-238.5%+237.3%
YOY-8.2%-288.4%+280.2%
5Y-1.9%-486.2%+484.3%
10Y-15,150.3%-628.4%-14,521.9%
1.2.2. Operating Ratio

Measures how efficient Cyxone is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Cyxone AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.123-0.123
TTM0.123YOY0.096+0.027
TTM0.1235Y0.044+0.079
5Y0.04410Y151.562-151.519
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM0.1233.310-3.187
YOY0.0963.838-3.742
5Y0.0445.679-5.635
10Y151.5627.823+143.739

1.3. Liquidity of Cyxone AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cyxone is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.01 means the company has kr4.01 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Cyxone AB:

  • The MRQ is 4.010. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.321. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.010TTM3.321+0.689
TTM3.321YOY7.052-3.731
TTM3.3215Y7.601-4.280
5Y7.60110Y10.843-3.242
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0103.863+0.147
TTM3.3214.169-0.848
YOY7.0525.337+1.715
5Y7.6016.122+1.479
10Y10.8436.434+4.409
1.3.2. Quick Ratio

Measures if Cyxone is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cyxone to the Biotechnology industry mean.
  • A Quick Ratio of 3.90 means the company can pay off kr3.90 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cyxone AB:

  • The MRQ is 3.902. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.212. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.902TTM3.212+0.690
TTM3.212YOY6.977-3.765
TTM3.2125Y7.501-4.289
5Y7.50110Y10.701-3.200
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9023.504+0.398
TTM3.2123.991-0.779
YOY6.9775.371+1.606
5Y7.5016.088+1.413
10Y10.7016.395+4.306

1.4. Solvency of Cyxone AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cyxone assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cyxone to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Cyxone assets are financed with 10.8% credit (debt) and the remaining percentage (100% - 10.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cyxone AB:

  • The MRQ is 0.108. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.135. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.108TTM0.135-0.028
TTM0.135YOY0.121+0.015
TTM0.1355Y0.111+0.025
5Y0.11110Y0.097+0.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1080.339-0.231
TTM0.1350.337-0.202
YOY0.1210.271-0.150
5Y0.1110.368-0.257
10Y0.0970.388-0.291
1.4.2. Debt to Equity Ratio

Measures if Cyxone is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cyxone to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.0% means that company has kr0.12 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cyxone AB:

  • The MRQ is 0.120. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.148. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.120TTM0.148-0.028
TTM0.148YOY0.138+0.010
TTM0.1485Y0.131+0.017
5Y0.13110Y0.112+0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1200.392-0.272
TTM0.1480.403-0.255
YOY0.1380.335-0.197
5Y0.1310.427-0.296
10Y0.1120.461-0.349

2. Market Valuation of Cyxone AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Cyxone generates.

  • Above 15 is considered overpriced but always compare Cyxone to the Biotechnology industry mean.
  • A PE ratio of -0.78 means the investor is paying kr-0.78 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cyxone AB:

  • The EOD is -0.717. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.775. Based on the earnings, the company is expensive. -2
  • The TTM is -3.400. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.717MRQ-0.775+0.059
MRQ-0.775TTM-3.400+2.625
TTM-3.400YOY-5.570+2.170
TTM-3.4005Y-17.403+14.003
5Y-17.40310Y-69.562+52.160
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.717-2.300+1.583
MRQ-0.775-2.656+1.881
TTM-3.400-2.718-0.682
YOY-5.570-4.145-1.425
5Y-17.403-6.258-11.145
10Y-69.562-6.315-63.247
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cyxone AB:

  • The EOD is -0.855. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.925. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.847. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.855MRQ-0.925+0.070
MRQ-0.925TTM-2.847+1.923
TTM-2.847YOY-3.549+0.701
TTM-2.8475Y-17.886+15.039
5Y-17.88610Y-1,327.953+1,310.067
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.855-2.974+2.119
MRQ-0.925-3.306+2.381
TTM-2.847-3.508+0.661
YOY-3.549-5.613+2.064
5Y-17.886-8.378-9.508
10Y-1,327.953-8.873-1,319.080
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cyxone is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.56 means the investor is paying kr0.56 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Cyxone AB:

  • The EOD is 0.514. Based on the equity, the company is cheap. +2
  • The MRQ is 0.556. Based on the equity, the company is cheap. +2
  • The TTM is 2.397. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.514MRQ0.556-0.042
MRQ0.556TTM2.397-1.840
TTM2.397YOY2.668-0.271
TTM2.3975Y11.464-9.067
5Y11.46410Y23.124-11.660
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5141.914-1.400
MRQ0.5562.116-1.560
TTM2.3972.097+0.300
YOY2.6682.881-0.213
5Y11.4643.550+7.914
10Y23.1243.936+19.188
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Cyxone AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.034-0.009+127%0.009+284%-0.007+121%0.006+470%
Book Value Per Share--0.1800.163+11%0.264-32%0.243-26%0.216-17%
Current Ratio--4.0103.321+21%7.052-43%7.601-47%10.843-63%
Debt To Asset Ratio--0.1080.135-21%0.121-11%0.111-3%0.097+11%
Debt To Equity Ratio--0.1200.148-19%0.138-13%0.131-8%0.112+7%
Dividend Per Share----0%-0%-0%-0%
Eps---0.032-0.028-14%-0.050+53%-0.045+40%-0.034+6%
Free Cash Flow Per Share---0.027-0.031+14%-0.057+111%-0.046+70%-0.039+44%
Free Cash Flow To Equity Per Share--0.042-0.014+134%0.000+68938%0.030+37%0.026+58%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.177--------
Intrinsic Value_10Y_min---0.214--------
Intrinsic Value_1Y_max---0.160--------
Intrinsic Value_1Y_min---0.158--------
Intrinsic Value_3Y_max---0.373--------
Intrinsic Value_3Y_min---0.358--------
Intrinsic Value_5Y_max---0.455--------
Intrinsic Value_5Y_min---0.432--------
Market Cap20037932.800-8%21678970.40079860231.100-73%152551719.000-86%610783398.420-96%892626567.947-98%
Net Profit Margin----0.0140%-0.0840%-0.0190%-151.3800%
Operating Margin----0.0120%-0.0820%-0.0190%-151.5030%
Operating Ratio---0.123-100%0.096-100%0.044-100%151.562-100%
Pb Ratio0.514-8%0.5562.397-77%2.668-79%11.464-95%23.124-98%
Pe Ratio-0.717+8%-0.775-3.400+339%-5.570+618%-17.403+2145%-69.562+8873%
Price Per Share0.093-8%0.1000.370-73%0.707-86%2.829-96%4.134-98%
Price To Free Cash Flow Ratio-0.855+8%-0.925-2.847+208%-3.549+284%-17.886+1835%-1327.953+143532%
Price To Total Gains Ratio2.709-8%2.930-3.435+217%-19.778+775%-45.511+1653%-81.099+2868%
Quick Ratio--3.9023.212+21%6.977-44%7.501-48%10.701-64%
Return On Assets---0.160-0.150-7%-0.157-2%-0.167+4%-0.134-16%
Return On Equity---0.179-0.164-8%-0.180+0%-0.189+5%-0.151-16%
Total Gains Per Share--0.034-0.009+127%0.009+284%-0.007+121%0.006+470%
Usd Book Value--3580607.8003224862.900+11%5247007.525-32%4829363.899-26%4291825.793-17%
Usd Book Value Change Per Share--0.003-0.001+127%0.001+284%-0.001+121%0.001+470%
Usd Book Value Per Share--0.0170.015+11%0.024-32%0.022-26%0.020-17%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.003-0.003-14%-0.005+53%-0.004+40%-0.003+6%
Usd Free Cash Flow---538717.800-611640.450+14%-1137055.725+111%-917460.785+70%-777161.614+44%
Usd Free Cash Flow Per Share---0.002-0.003+14%-0.005+111%-0.004+70%-0.004+44%
Usd Free Cash Flow To Equity Per Share--0.004-0.001+134%0.000+68938%0.003+37%0.002+58%
Usd Market Cap1841486.024-8%1992297.3807339155.238-73%14019502.976-86%56130994.315-96%82032381.594-98%
Usd Price Per Share0.009-8%0.0090.034-73%0.065-86%0.260-96%0.380-98%
Usd Profit---642472.900-552732.550-14%-983421.900+53%-900888.697+40%-682235.111+6%
Usd Revenue----0%147017.025-100%29403.405-100%19605.333-100%
Usd Total Gains Per Share--0.003-0.001+127%0.001+284%-0.001+121%0.001+470%
 EOD+2 -6MRQTTM+20 -10YOY+19 -125Y+20 -1110Y+16 -15

3.2. Fundamental Score

Let's check the fundamental score of Cyxone AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.717
Price to Book Ratio (EOD)Between0-10.514
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.902
Current Ratio (MRQ)Greater than14.010
Debt to Asset Ratio (MRQ)Less than10.108
Debt to Equity Ratio (MRQ)Less than10.120
Return on Equity (MRQ)Greater than0.15-0.179
Return on Assets (MRQ)Greater than0.05-0.160
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Cyxone AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.097
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets43,655
Total Liabilities4,693
Total Stockholder Equity38,961
 As reported
Total Liabilities 4,693
Total Stockholder Equity+ 38,961
Total Assets = 43,655

Assets

Total Assets43,655
Total Current Assets18,523
Long-term Assets25,132
Total Current Assets
Cash And Cash Equivalents 17,528
Net Receivables 494
Other Current Assets 501
Total Current Assets  (as reported)18,523
Total Current Assets  (calculated)18,523
+/-0
Long-term Assets
Property Plant Equipment 1,142
Long-term Assets Other 23,645
Long-term Assets  (as reported)25,132
Long-term Assets  (calculated)24,787
+/- 345

Liabilities & Shareholders' Equity

Total Current Liabilities4,619
Long-term Liabilities74
Total Stockholder Equity38,961
Total Current Liabilities
Short-term Debt 784
Accounts payable 1,827
Other Current Liabilities 1,806
Total Current Liabilities  (as reported)4,619
Total Current Liabilities  (calculated)4,417
+/- 202
Long-term Liabilities
Long-term Liabilities  (as reported)74
Long-term Liabilities  (calculated)0
+/- 74
Total Stockholder Equity
Common Stock8,637
Retained Earnings -216,137
Other Stockholders Equity 246,461
Total Stockholder Equity (as reported)38,961
Total Stockholder Equity (calculated)38,961
+/-0
Other
Cash and Short Term Investments 17,528
Common Stock Shares Outstanding 129,092
Current Deferred Revenue202
Liabilities and Stockholders Equity 43,655
Net Debt -16,670
Net Working Capital 13,904
Short Long Term Debt Total 858



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
> Total Assets 
0
25,803
24,709
23,562
33,360
31,682
30,101
41,065
37,956
32,991
42,926
75,670
68,568
65,105
60,064
75,115
64,965
53,637
57,095
72,152
62,482
69,240
58,567
46,128
84,986
65,926
56,786
52,527
47,131
35,132
36,091
43,655
43,65536,09135,13247,13152,52756,78665,92684,98646,12858,56769,24062,48272,15257,09553,63764,96575,11560,06465,10568,56875,67042,92632,99137,95641,06530,10131,68233,36023,56224,70925,8030
   > Total Current Assets 
0
25,208
23,787
21,963
31,515
28,497
25,846
33,499
27,460
18,086
12,121
39,268
30,593
24,335
12,788
62,420
52,718
41,681
45,569
57,278
48,056
55,263
45,039
32,157
70,961
50,375
41,825
30,411
23,675
16,229
9,502
18,523
18,5239,50216,22923,67530,41141,82550,37570,96132,15745,03955,26348,05657,27845,56941,68152,71862,42012,78824,33530,59339,26812,12118,08627,46033,49925,84628,49731,51521,96323,78725,2080
       Cash And Cash Equivalents 
0
24,636
23,468
21,598
31,275
28,114
25,662
33,357
27,227
17,817
10,478
38,716
30,049
23,872
12,307
61,756
51,831
40,630
44,587
56,343
47,268
54,054
42,963
29,357
69,194
48,582
40,889
29,246
22,394
15,058
8,497
17,528
17,5288,49715,05822,39429,24640,88948,58269,19429,35742,96354,05447,26856,34344,58740,63051,83161,75612,30723,87230,04938,71610,47817,81727,22733,35725,66228,11431,27521,59823,46824,6360
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
625
596
787
580
550
399
654
1,311
1,015
1,312
1,337
573
582
621
548
562
494
4945625486215825731,3371,3121,0151,311654399550580787596625000000000000000
       Other Current Assets 
0
572
319
365
240
383
184
142
233
269
1,643
552
544
463
481
664
887
1,051
982
935
788
1,209
2,076
1
-1
1,793
936
2
660
623
1
501
501162366029361,793-112,0761,2097889359821,0518876644814635445521,6432692331421843832403653195720
   > Long-term Assets 
0
595
922
1,599
1,845
3,185
4,255
7,566
10,496
14,905
30,805
36,402
37,975
40,770
47,276
12,696
12,247
11,956
11,526
14,874
14,426
13,977
13,528
13,972
14,025
15,551
14,961
22,116
23,456
23,384
26,589
25,132
25,13226,58923,38423,45622,11614,96115,55114,02513,97213,52813,97714,42614,87411,52611,95612,24712,69647,27640,77037,97536,40230,80514,90510,4967,5664,2553,1851,8451,5999225950
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,966
1,814
1,646
1,627
1,441
1,255
1,142
1,1421,2551,4411,6271,6461,8141,9660000000000000000000000000
       Intangible Assets 
0
0
0
0
0
3,185
4,255
7,566
10,496
14,905
30,805
36,402
37,975
39,815
46,321
11,741
11,292
11,001
10,552
14,855
14,407
13,958
13,510
13,953
13,643
13,245
12,807
20,126
21,485
23,384
24,994
0
024,99423,38421,48520,12612,80713,24513,64313,95313,51013,95814,40714,85510,55211,00111,29211,74146,32139,81537,97536,40230,80514,90510,4967,5664,2553,18500000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
33,413
39,988
0
0
0
19
19
19
19
18
-1
382
340
340
3
0
-4,481
0
0
00-4,48103340340382-1181919191900039,98833,4130000000000000
> Total Liabilities 
0
3,115
570
730
604
1,511
1,448
3,933
3,571
2,362
4,001
5,121
2,781
3,685
4,409
3,378
3,411
6,270
20,489
5,047
3,989
5,112
5,390
6,896
12,340
5,925
8,000
5,581
6,158
6,267
4,527
4,693
4,6934,5276,2676,1585,5818,0005,92512,3406,8965,3905,1123,9895,04720,4896,2703,4113,3784,4093,6852,7815,1214,0012,3623,5713,9331,4481,5116047305703,1150
   > Total Current Liabilities 
0
3,115
570
730
604
1,511
1,448
3,933
3,571
2,362
4,001
5,121
2,781
3,685
4,409
3,378
3,411
6,270
20,489
5,047
3,989
5,112
5,391
6,897
12,341
4,879
7,117
4,860
5,541
5,834
4,278
4,619
4,6194,2785,8345,5414,8607,1174,87912,3416,8975,3915,1123,9895,04720,4896,2703,4113,3784,4093,6852,7815,1214,0012,3623,5713,9331,4481,5116047305703,1150
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
645
721
726
731
784
784731726721645000000000000000000000000000
       Accounts payable 
0
218
242
398
169
925
826
3,079
2,689
1,076
2,283
4,026
1,041
2,295
2,935
1,694
2,316
4,626
3,805
2,577
2,310
1,886
2,537
3,215
9,325
1,826
4,414
1,842
2,282
1,927
2,140
1,827
1,8272,1401,9272,2821,8424,4141,8269,3253,2152,5371,8862,3102,5773,8054,6262,3161,6942,9352,2951,0414,0262,2831,0762,6893,0798269251693982422180
       Other Current Liabilities 
0
2,897
328
332
435
586
622
854
882
1,286
1,718
1,095
1,740
1,390
1,474
1,684
1,095
1,644
16,684
2,470
1,679
3,226
2,854
3,682
3,016
3,053
2,703
2,373
3,259
3,907
2,138
1,806
1,8062,1383,9073,2592,3732,7033,0533,0163,6822,8543,2261,6792,47016,6841,6441,0951,6841,4741,3901,7401,0951,7181,2868828546225864353323282,8970
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
-1
-1
1,046
883
721
617
433
249
74
742494336177218831,046-1-1-10000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,046
884
721
617
433
248
0
02484336177218841,0460000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
-1
-1
1,046
883
0
0
0
0
0
000008831,046-1-1-10000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
33,413
39,988
0
0
0
0
0
0
0
0
0
0
0
0
6,399
0
9,626
0
0
009,62606,39900000000000039,98833,4130000000000000
> Total Stockholder Equity
0
22,688
24,139
22,832
32,756
30,171
28,653
37,132
34,385
30,629
38,925
70,549
65,787
61,420
55,655
71,737
61,554
47,367
36,606
67,105
58,493
64,128
53,177
39,232
72,646
60,001
48,786
46,946
40,973
35,132
31,564
38,961
38,96131,56435,13240,97346,94648,78660,00172,64639,23253,17764,12858,49367,10536,60647,36761,55471,73755,65561,42065,78770,54938,92530,62934,38537,13228,65330,17132,75622,83224,13922,6880
   Common Stock
0
975
975
975
1,157
1,157
1,157
1,343
1,343
1,343
1,488
2,827
2,827
2,827
2,827
3,704
3,704
3,704
3,736
4,382
4,382
4,806
4,806
4,806
7,430
7,430
7,430
7,430
7,430
7,430
7,430
8,637
8,6377,4307,4307,4307,4307,4307,4307,4304,8064,8064,8064,3824,3823,7363,7043,7043,7042,8272,8272,8272,8271,4881,3431,3431,3431,1571,1571,1579759759750
   Retained Earnings Total Equity00000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
133
136
210
124
0
0124210136133000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44,818
154,521
68,033
68,033
146,120
168,416
168,410
185,078
185,078
185,078
232,530
232,530
232,530
232,530
232,530
232,530
232,530
0
0232,530232,530232,530232,530232,530232,530232,530185,078185,078185,078168,410168,416146,12068,03368,033154,52144,81800000000000000
   Treasury Stock00000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
35,789
35,789
48,330
96,141
67,722
67,722
67,722
154,521
68,033
68,033
69,848
168,372
168,372
185,040
185,063
185,106
232,575
232,639
232,720
232,529
232,530
232,529
232,529
246,461
246,461232,529232,529232,530232,529232,720232,639232,575185,106185,063185,040168,372168,37269,84868,03368,033154,52167,72267,72267,72296,14148,33035,78935,78900000000



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-2,537
Gross Profit-2,537-2,537
 
Operating Income (+$)
Gross Profit-2,537
Operating Expense-19,233
Operating Income-21,770-21,770
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense19,2330
 
Net Interest Income (+$)
Interest Income0
Interest Expense-37
Other Finance Cost-14
Net Interest Income-51
 
Pretax Income (+$)
Operating Income-21,770
Net Interest Income-51
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-22,988-20,552
EBIT - interestExpense = -21,807
-22,987
-22,952
Interest Expense37
Earnings Before Interest and Taxes (EBIT)-21,770-22,951
Earnings Before Interest and Taxes (EBITDA)-19,233
 
After tax Income (+$)
Income Before Tax-22,988
Tax Provision--2
Net Income From Continuing Ops-17,542-22,986
Net Income-22,989
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses21,770
Total Other Income/Expenses Net-1,21851
 

Technical Analysis of Cyxone
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cyxone. The general trend of Cyxone is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cyxone's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cyxone AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.0996 < 0.109 < 0.114.

The bearish price targets are: 0.0795 > 0.078.

Tweet this
Cyxone AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cyxone AB. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cyxone AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cyxone AB.

Cyxone AB Daily Moving Average Convergence/Divergence (MACD) ChartCyxone AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cyxone AB. The current adx is .

Cyxone AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cyxone AB.

Cyxone AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cyxone AB.

Cyxone AB Daily Relative Strength Index (RSI) ChartCyxone AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cyxone AB.

Cyxone AB Daily Stochastic Oscillator ChartCyxone AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cyxone AB.

Cyxone AB Daily Commodity Channel Index (CCI) ChartCyxone AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cyxone AB.

Cyxone AB Daily Chande Momentum Oscillator (CMO) ChartCyxone AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cyxone AB.

Cyxone AB Daily Williams %R ChartCyxone AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cyxone AB.

Cyxone AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cyxone AB.

Cyxone AB Daily Average True Range (ATR) ChartCyxone AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cyxone AB.

Cyxone AB Daily On-Balance Volume (OBV) ChartCyxone AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cyxone AB.

Cyxone AB Daily Money Flow Index (MFI) ChartCyxone AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cyxone AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Cyxone AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cyxone AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.097
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cyxone with someone you think should read this too:
  • Are you bullish or bearish on Cyxone? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cyxone? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cyxone AB

I send you an email if I find something interesting about Cyxone AB.


Comments

How you think about this?

Leave a comment

Stay informed about Cyxone AB.

Receive notifications about Cyxone AB in your mailbox!